Beta Bionics, Inc. january 12, 2026 Please complete the form below to contact Kaplan Fox regarding the Beta Bionics Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating Beta Bionics, Inc. (BBNX) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Beta Bionics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas, an automated insulin delivery system. According to the Company’s press release dated January 8, 2026, “[t]he iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose.” On January 8, 2026, after markets closed, Beta Bionics announced its preliminary, unaudited topline financial results and key metrics for the fourth quarter of 2025. The Company reported “[n]ew patient starts expected to be at least 5,581” for the fourth quarter of 2025. An analyst at Bloomberg reportedly stated that “Beta’s 5,581 new-patient starts fell short of the 6,078 consensus expectation.” An analyst at Leerink Partners reportedly stated that “the -4% miss for new customer starts (NCS) may be a source of near-term volatility for the stock.” Following this news, on January 9, 2026, the price of Beta Bionics stock declined from a closing price on January 8, 2026 of $31.99 per share, to close at $20.14 per share, a decline of $11.85 per share, or by 37%. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Beta Bionics, Inc. See the Case Varonis Systems, Inc. See the Case Klarna Group PLC See the Case Quantum Biopharma Ltd. See the Case Corcept Therapeutics, Inc. See the Case CoreWeave, Inc. See the Case Coupang, Inc. See the Case James Hardie Industries plc See the Case DexCom, Inc. See the Case Stride, Inc. See the Case Organon & Co See the Case Marex Group plc See the Case
